Get the latest tech news
Isomorphic Labs partners with pharmaceutical firms for AI-driven drug discovery
London-based AI startup Isomorphic Labs concentrates on drug discovery and emerged from Google's DeepMind division has revealed partnerships for AI- driven pharmaceuticals.
By joining forces with these industry-leading pharmaceutical companies, Isomorphic Labs aims to leverage its groundbreaking AI technology to revolutionize the process of drug development and enhance the overall effectiveness of treatments. Established by CEO Demis Hassabis, Isomorphic Labs is behind AlphaFold, an AI system that predicts human protein structures and allows researchers to find potential new drug target pathways. According to Hassabis, these partnerships provide a “compelling” mix of innovative drug design techniques and cutting-edge science, potentially alleviating financial stress on Isomorphic Labs, which experienced a $2.4 million loss in 2021.
Or read this on ReadWrite